Meanwhile, several PLK1 kinase inhibitors have been developed as anticancer drugs and are currently being evaluated in clinical trials [6]: BI-2536, a dihydropteridinone compound and potent ATP-competitive PLK1 inhibitor [7], was found to inhibit cell proliferation in several human cancer cells, including breast, colon, lung, pancreas and prostate cancer [8]. The gene discussed is PLK1; the disease is prostate carcinoma.